Literature DB >> 8938270

Definition of tumor antigens suitable for vaccine construction.

J J Lewis1, A N Houghton.   

Abstract

The treatment of cancer with tumor vaccines has been a goal of physicians and scientists ever since effective immunization against infectious disease with vaccines was developed. In the past, major tumor antigens had not been molecularly characterized. Recent advances are, however, beginning to define potential molecular targets and strategies and this had evolved with the principle that T-cell mediated responses are a key target for approaches to cancer immunization. In addition, these antigens are not truly foreign and tumour antigens fit more with a self/altered self paradigm, compared to a non-self paradigm for antigens recognized in infectious diseases. Potential antigens include the glycolipids and glycoproteins (e.g. gangliosides), the developmental antigens (e.g. MAGE, tyrosinase, melan-A and gp75) and mutant oncogene products (e.g. p53, ras, and HER-2/neu). Innovations for construction of cancer vaccines are emerging from these advances in molecular immunology and cancer biology. While vaccines against infectious agents are models for vaccine development, there are clearly distinct considerations and problems associated with cancer vaccines. One of the focal issues in designing active cancer immunotherapy is that cancer cells are derived from normal host cells. Thus, the antigenic profile of cancer cells closely mimics that of normal cells. How the immune system identifies and destroys cancer cells is therefore crucial. Clearly, the ultimate goal of tumor vaccine design is the generation of antigen-specific vaccines. The recent success identifying molecularly defined tumor antigens opens up potentially novel strategies for this approach. Vaccine possibilities include purified proteins and glycolipids, peptides, cDNA expressed in various vectors, and a range of immune adjuvants. The molecular and structural definition of tumor antigens provides an opportunity for cautious optimism that we are entering an era when we will soon begin to recapitulate the success of immunization against infectious disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8938270     DOI: 10.1016/1044-579x(95)90001-2

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  8 in total

1.  Effect of early immunization on the formation of the antitumor resistance system in mice.

Authors:  S D Kaz'min; I N Todor
Journal:  Dokl Biol Sci       Date:  2001 Jul-Aug

Review 2.  Prospects for the therapeutic use of anticancer vaccines.

Authors:  R S Chamberlain
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 3.  Intraperitoneal immunotherapy: historical perspectives and modern therapy.

Authors:  W F Morano; A Aggarwal; P Love; S D Richard; J Esquivel; W B Bowne
Journal:  Cancer Gene Ther       Date:  2016-11-11       Impact factor: 5.987

4.  Effect of reresection in extremity soft tissue sarcoma.

Authors:  J J Lewis; D Leung; J Espat; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

Review 5.  Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution.

Authors:  J J Lewis; D Leung; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

Review 6.  Therapeutic cancer vaccines: using unique antigens.

Authors:  Jonathan J Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

Review 7.  Therapeutic Immunization against Glioblastoma.

Authors:  Virgil E J C Schijns; Chrystel Pretto; Anna M Strik; Rianne Gloudemans-Rijkers; Laurent Deviller; Denis Pierre; Jinah Chung; Manisha Dandekar; Jose A Carrillo; Xiao-Tang Kong; Beverly D Fu; Frank P K Hsu; Florence M Hofman; Thomas C Chen; Raphael Zidovetzki; Daniela A Bota; Apostolos Stathopoulos
Journal:  Int J Mol Sci       Date:  2018-08-27       Impact factor: 5.923

Review 8.  Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis.

Authors:  Anusha Thadi; Marian Khalili; William F Morano; Scott D Richard; Steven C Katz; Wilbur B Bowne
Journal:  Vaccines (Basel)       Date:  2018-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.